12:00 AM
 | 
Oct 04, 2004
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion
AtheroGenics (AGIX) Lazard Joel Sendek Price target Buy
Needham Mark Monane New Underperform
Sendek raised his target to $71 from $27 to reflect the value of AGI-1067. Based on positive interim results from the Phase IIb CART-2 trial, he expects positive data from the Phase III ARISE trial and a partnership...

Read the full 399 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >